文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

德国双中心单组试验:局限期前列腺癌大分割SBRT可行性研究

Hypo-fractionated SBRT for localized prostate cancer: a German bi-center single treatment group feasibility trial.
PubMed 文献 · Radiat Oncol · 2017-08-18

HYPOSTAT试验为德国双中心单组可行性研究,评估局限期低中危前列腺癌5次7 Gy极端大分割SBRT的毒性与PSA反应。靶区含前列腺(酌情含精囊基底),不确定边界3-5 mm,采用CyberKnife系统。假设≥2级副作用比例≤2.8%,计划入组85例,目前正在招募。

要点

  • 采用5次7 Gy极端大分割SBRT治疗局限期低中危前列腺癌。
  • 主要评估毒性与PSA反应,假设≥2级副作用比例≤2.8%。
  • 靶区边界3-5 mm,使用CyberKnife机器人系统实施。

核心结论

  • 该试验旨在验证德国开展前列腺癌极端大分割SBRT的可行性与有效性。

研究设计与样本

  • 德国双中心单组试验(HYPOSTAT),计划入组85例局限期低中危前列腺癌患者。

主要发现

  • 原文未报告试验结果,研究仍在进行并招募患者。

关键数值与推荐

  • SBRT方案为5次7 Gy,靶区为前列腺酌情含精囊基底,不确定边界3-5 mm。
  • 假设≥2级副作用比例≤2.8%,显著低于标准EBRT的17.5%。
  • 急性和晚期毒性按CTCAE v4.0、RTOG和IPSS评估,生活质量用EORTC QLQ C30评估。

临床怎么用

  • 可作为未来多中心或多平台研究及随机对照试验的先行研究。
  • 采用公立大学诊所入组随访、私立放疗机构实施治疗的独特试验模式。

局限性

  • 原文未报告长期结果,其他国家初步结果有前景但长期数据尚不可用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: For prostate cancer treatment, treatment options with minimal side effects are desired. External beam radiation therapy (EBRT) is non-invasive, standard of care and delivered in either conventional fractionation over 8 weeks or with moderate hypo-fractionation over about 5 weeks. Recent advances in radiotherapy technology have made extreme hypo-fractionated stereotactic body radiation therapy (SBRT) of prostate cancer feasible, which has not yet been introduced as a standard treatment method in Germany. Initial results from other countries are promising, but long-term results are not yet available. The aim of this study is to investigate feasibility and effectiveness of SBRT for prostate cancer in Germany. METHODS/DESIGN: This German bi-center single group trial (HYPOSTAT) is designed to evaluate feasibility and effectiveness, as measured by toxicity and PSA-response, respectively, of an extreme hypo-fractionated SBRT regimen with five fractions of 7 Gy in treatment of localized low and intermediate risk prostate cancer. The target volume includes the prostate with or without the base of seminal vesicles depending on risk stratification and uncertainty margins that are kept at 3-5 mm. SBRT treatment is delivered with the robotic CyberKnife system, which was recently introduced in Germany. Acute and late toxicity after one year will be evaluated according to Common Terminology Criteria for Adverse Events (CTCAE v. 4.0), Radiation Therapy Oncology Group (RTOG) and International Prostate Symptom Score (IPSS) Scores. The quality of life will be assessed before and after treatment with the EORTC QLQ C30 questionnaire. Hypothesizing that the proportion of patients with grade 2 side effects or higher is less or equal than 2.8%, thus markedly lower than the standard EBRT percentage (17.5%), the recruitment target is 85 patients. DISCUSSION: The HYPOSTAT trial aims at demonstrating short term feasibility of extreme hypo-fractioned SBRT for the treatment of prostate cancer and might be used as the pilot study for a multi-center multi-platform or for randomized-controlled trials comparing conventional radiotherapy with SBRT for localized prostate cancer in the future. The study concept of patient enrollment, follow up and evaluation by multiple public university clinics and actual patient treatment in dedicated private radiosurgery practices with high-tech radiation equipment is unique for clinical trials. STUDY STATUS: The study is ongoing and currently recruiting patients. TRIAL REGISTRATION: Registration number: NCT02635256 ( clinicaltrials.gov ). Registered 8 December 2015.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Jiang P, Krockenberger K, Vonthein R, et al. Hypo-fractionated SBRT for localized prostate cancer: a German bi-center single treatment group feasibility trial. Radiat Oncol. 2017. PMID: 28821268. doi:10.1186/s13014-017-0872-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。